12:00 AM
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

XR5000: Began Phase II testing

Xenova Group plc (LSE:XEN; XNVA), Slough, U.K.
Product: XR5000
Business: Cancer
Therapeutic category: Cytotoxic
Target: Topoisomerase I and...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >